
Healthcare Global Enterprises Q3 FY24 Earnings Call Analysis
Revenue, margin, capex, fundraise and order book outlook from management commentary.
Management growth scorecard
Revenue
Category 3
Margin
Category 1
Fundraise
N/A
Order
N/A
Capex
Yes
2 of 3 growth signals are positive.
Full analysisRevenue guidance
Category 3- HCG aims to grow faster than the market, which is expanding at about 10-11% annually.
- Mature centers showed adjusted revenue growth of approximately 12% after accounting for operational adjustments.
- Emerging centers are expected to drive higher incremental growth, with some centers like Kolkata and Mumbai showing strong revenue growth (57% and 17% respectively).
- Capacity expansions planned (e.g., new 100-bed facility in North Bangalore and additional beds in Indore) will support volume growth without current capacity constraints.
- Increased ARPOB (Average Revenue per Occupied Bed) is a key lever for growth, with ARPOB already rising across many centers.
- Investments in clinical talent and technology (e.g., radiation machines) are expected to improve volume and revenue mix.
- HCG expects continued volume and revenue growth through new center ramp-ups, better service mix, and geographic expansion.
See what Healthcare Global Enterprises management said on margin guidance — free account, 30 seconds.
Fundraise plans
See what Healthcare Global Enterprises management said on order book — free account, 30 seconds.
Capex plans
YesTrack Healthcare Global Enterprises — get its next earnings analysis in your feed
How does Healthcare Global Enterprises rank vs peers in Healthcare Services?
Pro featureHow does Healthcare Global Enterprises rank in Healthcare Services?
Compare Healthcare Global Enterprises against every Healthcare Services company (Q3 FY24) on revenue, margins and earnings-call signals.
Continue your research
What Healthcare Global Enterprises's management said in earlier quarters
Others in Healthcare Services this season
- Chandan Healthca (Q2 FY27)
Q2 FY27 operating income: ₹57.94 Cr, up 45.04% YoY from ₹39.95 Cr (Page 8) . Key investor presentation takeaways from Chandan Healthcare Ltd's Q2 FY27 investor
- Invicta Diagnostic (Q2 FY27)
Revenue from operations for the half year ended September 30, 2026: ₹379.11 lakhs (Page 4). Key results statement takeaways from Invicta Diagnostic Ltd's Q2 FY2
- Unihealth Hosp (Q2 FY27)
1,270 million with a year-on-year (YoY) growth of 6.3% . Key results statement takeaways from Unihealth Hospitals Ltd's Q2 FY27 results statement — and how it r
- Sangani Hospital (Q2 FY27)
1008.56 lakhs (~11.8% increase). Key results statement takeaways from Sangani Hospitals Ltd's Q2 FY27 results statement — and how it ranks against sector peers.